Aminosalicylic Acid

Summary

Aminosalicylic Acid (CHEMBL1169) is an approved small-molecule antitubercular agent (ATC J04AA01); indicated across 5 conditions including tuberculosis and pulmonary tuberculosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J04AA01
• Indications: 5 conditions
• Clinical trials: 14
• Chemistry: 153.14 Da · C7H7NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1169
Name	Aminosalicylic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4649
ChEBI	CHEBI:27565
ATC	J04AA01
Molecular formula	C7H7NO3
Molecular weight	153.14
InChIKey	WUBBRNOQWQTFEX-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1N)O)C(=O)O

IUPAC name: 4-amino-2-hydroxybenzoic acid

ChEBI definition: An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.

Pharmacological roles (ChEBI): antitubercular agent.

Also known as: Aminosalicylate, Aminosalicylic acid, Aminosalicylic acid resin complex, Granupas, NSC-2083, P-aminosalicylic acid, Para-aminosalicylic acid, Parasal, Pas, Paser, Rezipas, p-aminosalicylic acid

Parent form; salt/anhydrous children: CHEMBL1200584, CHEMBL1200966, CHEMBL1343453, CHEMBL1378207, CHEMBL2096646, CHEMBL2105983

Patent coverage: 20,894 distinct patent families (51,677 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 51,605 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Tyrosine-protein phosphatase non-receptor type 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
tuberculosis	4	MONDO:0018076	MONDO:0018076

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pulmonary tuberculosis	3	MONDO:0006052	EFO:1000049
ulcerative colitis	2	MONDO:0005101	EFO:0000729
Crohn disease	2	MONDO:0005011	EFO:0000384

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	6
PHASE3	4
PHASE1	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02331823	PHASE4	UNKNOWN	Research on New Regimens for Retreatment Pulmonary Tuberculosis
NCT06081361	PHASE3	ACTIVE_NOT_RECRUITING	Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
NCT00984568	PHASE3	TERMINATED	Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)
NCT01320436	PHASE3	COMPLETED	Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
NCT02683733	PHASE3	UNKNOWN	Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis
NCT00417690	PHASE2	TERMINATED	High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn’s Disease
NCT00069498	PHASE1	COMPLETED	Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients
NCT03070405	PHASE1	UNKNOWN	The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects
NCT00000796	Not specified	COMPLETED	A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
NCT00905866	Not specified	COMPLETED	Quality of Life in Patients Undergoing Parathyroidectomy
NCT01875068	Not specified	TERMINATED	A Program of Physician Supervision to Improve the Quality of Patient Referrals From Nurse Practitioners and Physician Assistants
NCT02284087	Not specified	COMPLETED	Paired Associative Stimulation in Post-stroke Hand Motor Deficits
NCT04499495	Not specified	COMPLETED	Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea
NCT04938284	Not specified	COMPLETED	Combining PAS to Non-invasive VNS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol,	CPIC	G6PD

PharmGKB also curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).